Lessons to be learned from serum biomarkers in psoriasis and IBD – the potential role in SpA

References

• Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127–2137.
   PubMed Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1–44.
   PubMed Web of Science ®Google Scholar
• Van den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002;46:755–765.
   PubMed Web of Science ®Google Scholar
• Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187–1193.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000;356:385–390.
   PubMed Web of Science ®Google Scholar
• Paramarta JE, De Rycke L, Heijda TF, et al. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. Ann Rheum Dis. 2013;72:1793–1799.
   PubMed Web of Science ®Google Scholar
• Sieper J, Van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815–822.
   PubMed Web of Science ®Google Scholar
• Landewé R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis. 2014;73:39–47.
   PubMed Web of Science ®Google Scholar
• Feldtkeller E, Khan MA, Van der Heijde D, et al. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003;23:61–66.
   PubMed Web of Science ®Google Scholar
• Salvadorini G, Bandinelli F, Delle Sedie A, et al. Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades. Clin Exp Rheumatol. 2012;30:561–565.
   PubMed Web of Science ®Google Scholar
• Sorensen J, Hetland ML. Decreases in diagnostic delay are supported by sensitivity analyses. Ann Rheum Dis. 2014;73:e45–e45.
   Google Scholar
• De Gruttola VG, Clax P, Demets DL, et al. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a national institutes of health workshop. Control Clin Trials. 2001;1998:485–502.
   Google Scholar
• Rudwaleit M, Van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31.
   PubMed Web of Science ®Google Scholar
• Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs’ treatment effect on C-reactive protein. Rheumatology (Oxford). 2010;49:536–541.
   PubMed Web of Science ®Google Scholar
• Poddubnyy DA, Rudwaleit M, Listing J, et al. Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2010;69:1338–1341.
   PubMed Web of Science ®Google Scholar
• Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis. 2008;67:511–517.
   PubMed Web of Science ®Google Scholar
• De Vries MK, Van Eijk IC, Van der Horst-Bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum. 2009;61:1484–1490.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Rudwaleit M, Haibel H, et al. Rates and predictors of radiographic sacroiliitis progression over 2 years in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70:1369–1374.
   PubMed Web of Science ®Google Scholar
• Gratacós J, Collado A, Filella F, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33:927–931.
   PubMedGoogle Scholar
• Pedersen SJ, Hetland ML, Sørensen IJ, et al. Circulating levels of interleukin-6, vascular endothelial growth factor, YKL-40, matrix metalloproteinase-3, and total aggrecan in spondyloarthritis patients during 3 years of treatment with TNFα inhibitors. Clin Rheumatol. 2010;29:1301–1309.
   PubMed Web of Science ®Google Scholar
• Kane D, Roth J, Frosch M, et al. Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum. 2003;48:1676–1685.
   PubMed Web of Science ®Google Scholar
• Kruithof E, De Rycke L, Vandooren B, et al. Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum. 2006;54:1795–1804.
   PubMed Web of Science ®Google Scholar
• De Rycke L, Baeten D, Foell D, et al. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol. 2005;206:17–27.
   PubMed Web of Science ®Google Scholar
• Turina MC, Sieper J, Yeremenko N, et al. Calprotectin serum level is an independent marker for radiographic spinal progression in axial spondyloarthritis. Ann Rheum Dis. 2014;73:1746–1748.
   PubMed Web of Science ®Google Scholar
• Baeten DL, Demetter P, Cuvelier C, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis. 2000;59:945–953.
   PubMed Web of Science ®Google Scholar
• Baeten D, Kruithof E, De Rycke L, et al. Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients. Arthritis Rheum. 2004;50:2931–2941.
   PubMed Web of Science ®Google Scholar
• Drouart M, Saas P, Billot M, et al. High serum vascular endothelial growth factor correlates with disease activity of spondylarthropathies. Clin Exp Immunol. 2003;132:158–162.
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Conrad K, Haibel H, et al. Elevated serum level of the vascular endothelial growth factor predicts radiographic spinal progression in patients with axial spondyloarthritis. Ann Rheum Dis. 2014;73:2137–2143.
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Hermann KG, et al. Serum vascular endothelial growth factor levels lack predictive value in patients with active ankylosing spondylitis treated with golimumab. J Rheumatol. 2016;43:901–906.
   PubMed Web of Science ®Google Scholar
• Vandooren B, Kruithof E, Yu DTY, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum. 2004;50:2942–2953.
   PubMed Web of Science ®Google Scholar
• Chen C-H, Lin K-C, Yu DTY, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford). 2006;45:414–420.
   PubMed Web of Science ®Google Scholar
• Yang C, Gu J, Rihl M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum. 2004;51:691–699.
   PubMed Web of Science ®Google Scholar
• Pedersen SJ, Sørensen IJ, Lambert RGW, et al. Radiographic progression is associated with resolution of systemic inflammation in patients with axial spondylarthritis treated with tumor necrosis factor α inhibitors: a study of radiographic progression, inflammation on magnetic resonance imaging, and c. Arthritis Rheum. 2011;63:3789–3800.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Landewé R, Conner-Spady B, et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum. 2007;56:1846–1853.
   PubMed Web of Science ®Google Scholar
• Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med. 2007;13:156–163.
   PubMed Web of Science ®Google Scholar
• Klingberg E, Nurkkala M, Carlsten H, et al. Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol. 2014;41:1349–1356.
   PubMed Web of Science ®Google Scholar
• Kwon S-R, Lim M-J, Suh C-H, et al. Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int. 2012;32:2523–2527.
   PubMed Web of Science ®Google Scholar
• Heiland GR, Appel H, Poddubnyy D, et al. High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:572–574.
   PubMed Web of Science ®Google Scholar
• Appel H, Ruiz-Heiland G, Listing J, et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 2009;60:3257–3262.
   PubMed Web of Science ®Google Scholar
• Taylan A, Sari I, Akinci B, et al. Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2012;13:191.
   PubMed Web of Science ®Google Scholar
• De Andrade KR, De Castro GRW, Vicente G, et al. Evaluation of circulating levels of inflammatory and bone formation markers in axial spondyloarthritis. Int Immunopharmacol. 2014;21:481–486.
   PubMed Web of Science ®Google Scholar
• Korkosz M, Gąsowski J, Leszczyński P, et al. High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord. 2013 Mar 19;14:99. doi:10.1186/1471-2474-14-99.
   PubMed Web of Science ®Google Scholar
• Chou C-L, Wu M-J, Yu C-L, et al. Anti-agalactosyl IgG antibody in ankylosing spondylitis and psoriatic arthritis. Clin Rheumatol. 2010;29:875–881.
   PubMed Web of Science ®Google Scholar
• Wright C, Sibani S, Trudgian D, et al. Detection of multiple autoantibodies in patients with ankylosing spondylitis using nucleic acid programmable protein arrays. Mol Cell Proteomics. 2012 Feb;11(2):M9.00384. doi:10.1074/mcp.M9.00384.
   Web of Science ®Google Scholar
• Duftner C, Dejaco C, Klauser A, et al. High positive predictive value of specific antibodies cross-reacting with a 28-kDa Drosophila antigen for diagnosis of ankylosing spondylitis. Rheumatology (Oxford). 2006;45:38–42.
   PubMed Web of Science ®Google Scholar
• Baerlecken NT, Nothdorft S, Stummvoll GH, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis. 2014;73:1211–1214.
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Baerlecken N, Witte T, et al. High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis. 2014;73:1079–1082.
   PubMed Web of Science ®Google Scholar
• Baeten D, Breban M, Lories R, et al. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum. 2013;65:12–20.
   PubMed Web of Science ®Google Scholar
• Fredriksson T, Pettersson U. Severe psoriasis–oral therapy with a new retinoid. Dermatologica. 1978;157:238–244.
   PubMedGoogle Scholar
• Beygi S, Lajevardi V, Abedini R. C-reactive protein in psoriasis: a review of the literature. J Eur Acad Dermatol Venereol. 2014;28:700–711.
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatology Venereol. 2010;24:789–796.
   PubMed Web of Science ®Google Scholar
• Nisa N, Qazi A. High-sensitivity C-reactive protein in psoriasis. Int J Dermatol. 2012;51:1393–1394.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Malerbai M, Malara G, et al. C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis. Int J Immunopathol Pharmacol. 2010;23:1195–1202.
   PubMed Web of Science ®Google Scholar
• Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol. 2004;150:917–928.
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-α levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163:1282–1290.
   PubMed Web of Science ®Google Scholar
• Arican O, Aral M, Sasmaz S, et al. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm. 2005;2005:273–279.
   PubMed Web of Science ®Google Scholar
• Bonifati C, Trento E, Carducci M, et al. Soluble E-selectin and soluble tumour necrosis factor receptor (60 kD) serum levels in patients with psoriasis. Dermatology. 1995;190:128–131.
   PubMed Web of Science ®Google Scholar
• Ataseven A, Kesli R, Kurtipek GS, et al. Assessment of lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1, interleukin-6, homocysteine, and uric acid levels in patients with psoriasis. Dis Markers. 2014;2014:541709.
   PubMed Web of Science ®Google Scholar
• Serwin AB, Sokolowska M, Chodynicka B. Tumour necrosis factor a (TNF- alpha)-converting enzyme (TACE) and soluble TNF- a receptor type 1 in psoriasis patients treated with narrowband ultraviolet B. Photodermatol Photoimmunol Photomed. 2007;23:130–134.
   PubMed Web of Science ®Google Scholar
• Borská L, Fiala Z, Krejsek J, et al. Selected immunological changes in patients with sICAM-1 and IL-8. Physiol Res. 2006;55:699–706.
   PubMed Web of Science ®Google Scholar
• Elghandour TM, Youssef SES, Aly DG, et al. Effect of narrow band ultraviolet b therapy versus methotrexate on serum levels of interleukin-17 and interleukin-23 in Egyptian patients with severe psoriasis. Dermatol Res Pract. 2013;2013:618269.
   PubMedGoogle Scholar
• Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol. 2009;29:210–214.
   PubMed Web of Science ®Google Scholar
• Flisiak I, Klepacki A, Chodynicka B. Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity. Biomarkers. 2006;11:194–200.
   PubMed Web of Science ®Google Scholar
• Gangemi S, Merendino RA, Guarneri F, et al. Serum levels of interleukin-18 and s-ICAM-1 in patients affected by psoriasis : preliminary considerations. Eur Acad Dermatol Venereol. 2003;17:42–46.
   PubMed Web of Science ®Google Scholar
• Shimauchi T, Hirakawa S, Suzuki T, et al. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. J Dermatol. 2013;40:805–812.
   PubMed Web of Science ®Google Scholar
• Czech W, Schopf E, Kapp A. Soluble E-selectin in sera of patients with atopic dermatitis and psoriasis-correlation with disease activity. Br J Dermatol. 1996;134:17–21.
   PubMed Web of Science ®Google Scholar
• Szepietowski J, Wa F, Bielicka E, et al. Soluble E-selectin serum levels correlate with disease activity in psoriatic patients. Exp Dermatol. 1999;24:33–36.
   Web of Science ®Google Scholar
• Krasowska D, Chodorowska G, Kozioł M, et al. Plasma levels of sICAM-1 in patients affected by psoriasis: no relation to disease severity. Med Sci Monit. 2000;6:353–355.
   PubMedGoogle Scholar
• Madej A, Reich A, Orda A, et al. Vascular adhesion protein-1 (VAP-1) is overexpressed in psoriatic patients. J Eur Acad Dermatol Venereol. 2007;21:72–78.
   PubMed Web of Science ®Google Scholar
• Ataseven A, Kesli R. Novel inflammatory markers in psoriasis vulgaris: vaspin, vascular adhesion protein-1 (VAP-1), and YKL-40. G Ital Dermatol Venereol. 2016;151:244–250.
   PubMed Web of Science ®Google Scholar
• Nemati H, Khodarahmi R, Rahmani A, et al. Serum lipid profile in psoriatic patients: correlation between vascular adhesion protein 1 and lipoprotein (a). Cell Biochem Funct. 2013;31(February 2012):36–40.
   PubMed Web of Science ®Google Scholar
• Schonthaler HB, Guinea-Viniegra J, Wculek SK, et al. S100A8-S100A9 protein complex mediates psoriasis by regulating the expression of complement factor C3. Immunity. 2013;39:1171–1181.
   PubMed Web of Science ®Google Scholar
• Benoit S, Toksoy A, Ahlmann M, et al. Elevated serum levels of calcium-binding S 100 proteins A 8 and A 9 reflect disease activity and abnormal differentiation of keratinocytes in psoriasis. Clin Lab Investig. 2006;7:62–66.
   Google Scholar
• El-Hadidi H, Samir N, Shaker OG, et al. Estimation of tissue and serum lipocalin-2 in psoriasis vulgaris and its relation to metabolic syndrome. Arch Dermatol Res. 2014;306:239–245.
   PubMed Web of Science ®Google Scholar
• Kamata M, Tada Y, Tatsuta A, et al. Serum lipocalin-2 levels are increased in patients with psoriasis. Clin Exp Dermatol. 2012;37:296–299.
   PubMed Web of Science ®Google Scholar
• Romaní J, Caixàs A, Ceperuelo-Mallafré V, et al. Circulating levels of lipocalin-2 and retinol-binding protein-4 are increased in psoriatic patients and correlated with baseline PASI. Arch Dermatol Res. 2013;305:105–112.
   PubMed Web of Science ®Google Scholar
• Jansen PAM, Rodijk-Olthuis D, Hollox EJ, et al. Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin. PLoS One. 2009;4:e4725.
   PubMed Web of Science ®Google Scholar
• Gambichler T, Bechara FG, Scola N, et al. Serum levels of antimicrobial peptides and proteins do not correlate with psoriasis severity and are increased after treatment with fumaric acid esters. Arch Dermatol Res. 2012;304:471–474.
   PubMed Web of Science ®Google Scholar
• Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159:342–350.
   PubMed Web of Science ®Google Scholar
• Ozdemir M, Yüksel M, Gökbel H, et al. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporin. J Dermatol. 2012;39:443–448.
   PubMed Web of Science ®Google Scholar
• Kawashima K, Torii K, Furuhashi T, et al. Phototherapy reduces serum resistin levels in psoriasis patients. Photodermatol Photoimmunol Photomed. 2011;27:152–155.
   PubMed Web of Science ®Google Scholar
• Baran A, Flisiak I, Jaroszewicz J, et al. Serum adiponectin and leptin levels in psoriatic patients according to topical treatment. J Dermatolog Treat. 2014;6634:1–5.
   Google Scholar
• Karadag AS, Ertugrul DT, Kalkan G, et al. The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study. Dermatology. 2013;227:103–108.
   PubMed Web of Science ®Google Scholar
• Oh YJ, Lim HK, Choi JH, et al. Serum leptin and adiponectin levels in Korean patients with psoriasis. J Korean Med Sci. 2014;29:729–734.
   PubMed Web of Science ®Google Scholar
• Zhu K-J, Zhang C, Li M, et al. Leptin levels in patients with psoriasis: a meta-analysis. Clin Exp Dermatol. 2013;38:478–483.
   PubMed Web of Science ®Google Scholar
• Shibata S, Saeki H, Tada Y, et al. Serum high molecular weight adiponectin levels are decreased in psoriasis patients. J Dermatol Sci. 2009;55:62–63.
   PubMed Web of Science ®Google Scholar
• Shibata S, Tada Y, Hau C, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol. 2011;164:667–670.
   PubMed Web of Science ®Google Scholar
• Ucak H, Demir B, Cicek D, et al. Metabolic changes and serum ghrelin level in patients with psoriasis. Dermatol Res Pract. 2014;2014:1–6.
   Google Scholar
• Bhushan M, McLaughlin B, Weiss JB, et al. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol. 1999;141:1054–1060.
   PubMed Web of Science ®Google Scholar
• Meki A-RMA, Al-Shobaili H. Serum vascular endothelial growth factor, transforming growth factor β1, and nitric oxide levels in patients with psoriasis vulgaris: their correlation to disease severity. J Clin Lab Anal. 2014;28:496–501.
   PubMed Web of Science ®Google Scholar
• Flisiak I, Zaniewski P, Rogalska-Taranta M, et al. Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations. J Eur Acad Dermatol Venereol. 2012;26:302–307.
   PubMed Web of Science ®Google Scholar
• Tekin NS, Ilter N, Sancak B, et al. Nitric oxide levels in patients with psoriasis treated with methotrexate. Mediators Inflamm. 2006;2006:1–5.
   Web of Science ®Google Scholar
• Gokhale N, Belgaumkar V, Pandit D, et al. A study of serum nitric oxide levels in psoriasis. Indian J Dermatol Venereol Leprol. 2005;71:175.
   PubMedGoogle Scholar
• Zalewska A, Wyczółkowska J, Narbutt J, et al. Nitric oxide levels in plasma and fibroblast cultures of psoriasis vulgaris patients. J Dermatol Sci. 2007;48:237–240.
   PubMed Web of Science ®Google Scholar
• Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol. 2008;159:322–330.
   PubMed Web of Science ®Google Scholar
• Serwin AB, Wasowicz W, Chodynicka B. Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. Nutrition. 2006;22:860–864.
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatology Venereol. 2010;24:1386–1394.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Lora V, Bonauguri C, et al. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol. 2013;168:749–755.
   PubMed Web of Science ®Google Scholar
• Long JW, Tao J, Pi X, et al. Effect of narrow-band UVB phototherapy on soluble cell adhesion molecules in patients with psoriasis vulgaris. J Int Med Reserach. 2014;38:1507–1512.
   Google Scholar
• Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM. et al. Ankylosing spondylitis and inflammatory bowel disease. ii. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann Rheum Dis. 1978;37:33–35.
   PubMed Web of Science ®Google Scholar
• Orchard TR, Wordsworth BP, Jewell DP. Peripheral arthropathies in inflammatory bowel disease: their articular distribution and natural history. Gut. 1998;42:387–391.
   PubMed Web of Science ®Google Scholar
• Palm O, Moum B, Ongre A, et al. Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study). J Rheumatol. 2002;29:511–515.
   PubMed Web of Science ®Google Scholar
• Salvarani C. Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease. World J Gastroenterol. 2009;15:2449.
   PubMed Web of Science ®Google Scholar
• De Vos M, Cuvelier C, Mielants H, et al. Ileocolonoscopy in seronegative spondylarthropathy. Gastroenterology. 1989;96:339–344.
   PubMed Web of Science ®Google Scholar
• Van Praet L, Van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis. 2013;72:414–417.
   PubMed Web of Science ®Google Scholar
• Lees CW, Barrett JC, Parkes M, et al. New IBD genetics: common pathways with other diseases. Gut. 2011;60:1739–1753.
   PubMed Web of Science ®Google Scholar
• Harvey D, Pointon JJ, Evans DM, et al. Investigating the genetic association between ERAP1 and ankylosing spondylitis. Hum Mol Genet. 2009;18:4204–4212.
   PubMed Web of Science ®Google Scholar
• Reveille JD, Sims A-M, Danoy P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010;42:123–127.
   PubMed Web of Science ®Google Scholar
• Tremelling M, Cummings F, Fisher SA, et al. IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease. Gastroenterology. 2007;132:1657–1664.
   PubMed Web of Science ®Google Scholar
• Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010;16:112–124.
   PubMed Web of Science ®Google Scholar
• Best W, Becktel J, Singleton J Jr., et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.
   PubMed Web of Science ®Google Scholar
• Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29–32.
   PubMed Web of Science ®Google Scholar
• Schroeder K, Tremaine W, Ilstrup D. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987;317:1625–1629.
   PubMed Web of Science ®Google Scholar
• Poullis AP, Zar S, Sundaram KK, et al. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoea-predominant functional bowel disorders. Eur J Gastroenterol Hepatol. 2002;14:409–412.
   PubMed Web of Science ®Google Scholar
• Fagan E, Dyck R, Maton P, et al. Serum levels of C-reactive protein in Crohn’s disease and ulcerative colitis. Eur J Clin Invest. 1982;12:351–359.
   PubMed Web of Science ®Google Scholar
• Chamouard P, Richert Z, Meyer N, et al. Diagnostic value of C-reactive protein for predicting activity level of Crohn’s disease. Clin Gastroenterol Hepatol. 2006;4:882–887.
   PubMed Web of Science ®Google Scholar
• Jürgens M, Mahachie John JM, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2011;9:421–7.e1.
   PubMed Web of Science ®Google Scholar
• Louis E, Vermeire S, Rutgeerts P, et al. A positive response to infliximab in crohn disease: association with a higher systemic inflammation before treatment but not with - 308 TNF Gene Polymorphism. Scand J Clin Lab Invest. 2002;7:818–824.
   Google Scholar
• Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–712.
   PubMed Web of Science ®Google Scholar
• Wright J, Alp M, Young F, et al. Predictors of acute relapse of Crohn ’ s disease: a laboratory and clinical study. Dig Dis Sci. 1987;32:164–170.
   PubMed Web of Science ®Google Scholar
• Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in Crohn’s disease. Gut. 2005;54:488–495.
   PubMed Web of Science ®Google Scholar
• Koutroubakis IE, Petinaki E, Dimoulios P, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis. 2003;18:254–259.
   PubMed Web of Science ®Google Scholar
• Vind I, Johansen J, Price P, et al. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol. 2003;38:599–605.
   PubMed Web of Science ®Google Scholar
• Erzin Y, Uzun H, Karatas A, et al. Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn’s disease. J Gastroenterol Hepatol. 2008;23(8 Pt 2):e357–62.
   PubMed Web of Science ®Google Scholar
• Herrlinger KR, Dittmann R, Weitz G, et al. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis. Inflamm Bowel Dis. 2004;10:229–233.
   PubMed Web of Science ®Google Scholar
• Oruç N, Ozütemiz O, Osmanoğlu N, et al. Diagnostic value of serum procalcitonin in determining. Turkish J Gastroenterol. 2009;20:9–12.
   PubMed Web of Science ®Google Scholar
• Oussalah A, Laurent V, Bruot O, et al. Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn’s disease. Aliment Pharmacol Ther. 2010;32:1135–1144.
   PubMed Web of Science ®Google Scholar
• Sachar D, Smith H, Chan S, et al. Erythrocytic sedimentation rate as a measure of clinical activity in iflammatory bowel disease. J Clin Gastroenterol. 1986;8:647–650.
   PubMed Web of Science ®Google Scholar
• Balding J, Livingstone WJ, Conroy J, et al. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators Inflamm. 2004;13:181–187.
   PubMed Web of Science ®Google Scholar
• Shanahan F. Crohn’s disease. Lancet. 2002;359:62–69.
   PubMed Web of Science ®Google Scholar
• Gross V, Andus T, Caesar I, et al. Evidence for continuous stimulation of interleukin-6 production in Crohn ’s disease. Gastroenterology. 1992;102:514–519.
   PubMed Web of Science ®Google Scholar
• Hyams JS, Fitzgerald JE, Treem WR, et al. Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease. Gastroenterology. 1993;104:1285–1292.
   PubMed Web of Science ®Google Scholar
• Nancey S, Hamzaoui N, Moussata D, et al. Serum interleukin-6, soluble interleukin-6 receptor and Crohn’s disease activity. Dig Dis Sci. 2008;53:242–247.
   PubMed Web of Science ®Google Scholar
• Goke M, Hoffmann JC, Evers J, et al. Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. J Gastroenterol. 1997;32:480–486.
   PubMed Web of Science ®Google Scholar
• Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut. 1995;36:724–730.
   PubMed Web of Science ®Google Scholar
• Magro F, Araujo F, Pereira P, et al. Soluble selectins, sICAM, sVCAM, and angiogenic proteins in different activity groups of patients with inflammatory bowel disease. Dig Dis Sci. 2004;49(7–8):1265–1274.
   PubMed Web of Science ®Google Scholar
• Patel RT, Pall AA, Adu D, et al. Circulating soluble adhesion molecules in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 1995;7:1037–1041.
   PubMed Web of Science ®Google Scholar
• Song WB, Lv YH, Zhang ZS, et al. Soluble intercellular adhesion molecule-1, D-lactate and diamine oxidase in patients with inflammatory bowel disease. World J Gastroenterol. 2009;15:3916–3919.
   PubMed Web of Science ®Google Scholar
• Ates Y, Degertekin B, Erdil A, et al. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig Dis Sci. 2008;53:2215–2221.
   PubMed Web of Science ®Google Scholar
• Peracchi M, Bardella MT, Caprioli F, et al. Circulating ghrelin levels in patients with inflammatory bowel disease. Gut. 2006;55:432–433.
   PubMed Web of Science ®Google Scholar
• Sung EZH, Da Silva NF, Goodyear S, et al. Increased plasma ghrelin following infliximab in Crohn’s disease. Aliment Pharmacol Ther. 2009;29:83–89.
   PubMed Web of Science ®Google Scholar
• Kader N, El-Din F, Khatab E, et al. Does plasma resistin level have a role in predicting inflammatory bowel disease activity? Indian J Gastroenterol. 2010;29:126–127.
   PubMedGoogle Scholar
• Konrad A, Lehrke M, Schachinger V, et al. Resistin is an inflammatory marker of inflammatory bowel disease in humans. Eur J Gastroenterol Hepatol. 2007;19:1070–1074.
   PubMed Web of Science ®Google Scholar
• Morisaki T, Takeshima F, Fukuda H, et al. High serum vaspin concentrations in patients with ulcerative colitis. Dig Dis Sci. 2014;59:315–321.
   PubMed Web of Science ®Google Scholar
• Rodrigues VS, Milanski M, Fagundes JJ, et al. Serum levels and mesenteric fat tissue expression of adiponectin and leptin in patients with Crohn’s disease. Clin Exp Immunol. 2012;170:358–364.
   PubMed Web of Science ®Google Scholar
• Karmiris K, Koutroubakis IE, Xidakis C, et al. Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:100–105.
   PubMed Web of Science ®Google Scholar
• Weigert J, Obermeier F, Neumeier M, et al. Circulating levels of chemerin and adiponectin are higher in ulcerative colitis and chemerin is elevated in Crohn’s disease. Inflamm Bowel Dis. 2010;16:630–637.
   PubMed Web of Science ®Google Scholar
• Franchimont D, Roland S, Gustot T, et al. Impact of infliximab on serum leptin levels in patients with Crohn’s disease. J Clin Endocrinol Metab. 2005;90:3510–3516.
   PubMed Web of Science ®Google Scholar
• Karmiris K, Koutroubakis IE, Xidakis C, et al. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2007;19:789–794.
   PubMed Web of Science ®Google Scholar
• Manolakis AC, Kapsoritakis AN, Georgoulias P, et al. Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome. BMC Gastroenterol. 2010;10:118.
   PubMed Web of Science ®Google Scholar
• Brinar M, Cleynen I, Coopmans T, et al. Serum S100A12 as a new marker for inflammatory bowel disease and its relationship with disease activity. Gut. 2010;59:1728–1730.
   PubMed Web of Science ®Google Scholar
• Schimid KW, Lugering N, Stoll R, et al. Immunohistochemical demonstration of the calcium-binding proteins MRP8 and MRP14 and their heterodimer (27E 10 Antigen) in Crohn ’ s disease. Hum Pathol. 1995;26:334–337.
   PubMed Web of Science ®Google Scholar
• Lugering N, Stoll R, Schmid K, et al. The myeloic related protein MRP8/14 (27E10 antigen) - usefulness as a potential marker for disease activity in ulcerative colitis and putative biological function. Hum Pathol. 1995;14:659–664.
   Google Scholar
• Meuwis M, Vernier-Massouille G, Grimaud JC, et al. Serum calprotectin as a biomarker for Crohn’s disease. J Crohns Colitis. 2013;7:e678–83.
   PubMedGoogle Scholar
• Leach ST, Yang Z, Messina I, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1321–1331.
   PubMed Web of Science ®Google Scholar
• Malícková K, Kalousová M, Fucíková T, et al. Anti-inflammatory effect of biological treatment in patients with inflammatory bowel diseases: calprotectin and IL-6 changes do not correspond to sRAGE changes. Scand J Clin Lab Invest. 2010;70:294–299.
   PubMed Web of Science ®Google Scholar
• Von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803–813.
   PubMed Web of Science ®Google Scholar
• Van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. Bmj. 2010;341:c3369.
   PubMed Web of Science ®Google Scholar
• Lin J-F, Chen J-M, Zuo J-H, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407–1415.
   PubMed Web of Science ®Google Scholar
• Wagner M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584.
   PubMed Web of Science ®Google Scholar
• Sipponen T, Björkesten C-GAF, Färkkilä M, et al. Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment. Scand J Gastroenterol. 2010;45:325–331.
   PubMed Web of Science ®Google Scholar
• Kolho K-L, Sipponen T. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2014;49:434–441.
   PubMed Web of Science ®Google Scholar
• Hämäläinen A, Sipponen T, Kolho K-L. Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels. World J Gastroenterol. 2011;17:5166–5171.
   PubMed Web of Science ®Google Scholar
• Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M, et al. Fecal calprotectin as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy. J Clin Gastroenterol. 2016;50:147–151.
   Google Scholar
• Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn’s disease after surgery. Gastroenterology. 2015;148:938–947.e1.
   PubMed Web of Science ®Google Scholar
• Janas RM, Ochocińska A, Snitko R, et al. Neutrophil gelatinase-associated lipocalin in blood in children with inflammatory bowel disease. J Gastroenterol Hepatol. 2014;29:1883–1889.
   PubMed Web of Science ®Google Scholar
• Oikonomou KA, Kapsoritakis AN, Theodoridou C, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity. J Gastroenterol. 2012;47:519–530.
   PubMed Web of Science ®Google Scholar
• Yeşil A, Gönen C, Senateş E, et al. Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity. Dig Dis Sci. 2013;58:2587–2593.
   PubMed Web of Science ®Google Scholar
• Kim JM. Antimicrobial proteins in intestine and inflammatory bowel diseases. Intest Res. 2014;12:20–33.
   PubMedGoogle Scholar
• Yamaguchi N, Isomoto H, Mukae H, et al. Concentrations of alpha- and beta-defensins in plasma of patients with inflammatory bowel disease. Inflamm Res. 2009;58:192–197.
   PubMed Web of Science ®Google Scholar
• Zissis M, Afroudakis A, Galanopoulos G, et al. B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease? Am J Gastroenterol. 2001;96:2177–2183.
   Google Scholar
• Yılmaz B, Köklü S, Yüksel O, et al. Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease. World J Gastroenterol. 2014;20:10916–10920.
   PubMed Web of Science ®Google Scholar
• Dotan I. New serologic markers for inflammatory bowel disease diagnosis. Dig Dis. 2010;28:418–423.
   PubMed Web of Science ®Google Scholar
• Homsak E, Micetić-Turk D, Bozic B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value. Wien Klin Wochenschr. 2010;122(Suppl 2):19–25.
   PubMed Web of Science ®Google Scholar
• Kuna AT. Review Serological markers of inflammatory bowel disease. Biochem Med. 2013;23:28–42.
   PubMed Web of Science ®Google Scholar
• Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52:171–181.
   PubMed Web of Science ®Google Scholar
• Prideaux L, De Cruz P, Ng SC, et al. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis. 2012;18:1340–1355.
   PubMed Web of Science ®Google Scholar
• Peeters M, Ph D, Joossens S, et al. Diagnostic value of anti- saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol. 2001;96:731–734.
   Web of Science ®Google Scholar
• Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology. 1998;115:822–829.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Loftus EV, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative Colitis and Crohn’s disease. Inflamm Bowel Dis. 2001;7:192–201.
   PubMed Web of Science ®Google Scholar
• Esters N, Vermeire S, Joossens S, et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn’s disease. Am J Gastroenterol. 2002;97:1458–1462.
   PubMed Web of Science ®Google Scholar
• Smith BRK, Arnott IDR, Drummond HE, et al. Disease location, anti-saccharomyces cerevisiae Antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn’s disease. Inflamm Bowel Dis. 2004;10:521–528.
   PubMed Web of Science ®Google Scholar
• Bonneau J, Dumestre-Perard C, Rinaudo-Gaujous M, et al. Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes. Autoimmun Rev. 2015;14:231–245.
   PubMed Web of Science ®Google Scholar
• Karmiris K, Koutroubakis IE, Kouroumalis EA. Leptin, adiponectin, resistin, and ghrelin–implications for inflammatory bowel disease. Mol Nutr Food Res. 2008;52:855–866.
   PubMed Web of Science ®Google Scholar
• Sari I, Kebapcilar L, Taylan A, et al. Fetuin-A and interleukin-18 levels in ankylosing spondylitis. Int J Rheum Dis. 2010;13:75–81.
   PubMed Web of Science ®Google Scholar
• Wendling D, Racadot E, Auge B, et al. Soluble intercelulular adhesion molecule 1 in spondyloarthritis. Clin Rheumatol. 1998;17:202–204.
   PubMed Web of Science ®Google Scholar
• Kemeny-Beke A, Gesztelyi R, Bodnar N, et al. Increased production of asymmetric dimethylarginine (ADMA) and atherosclerotic disease in ankylosing spondylitis. Joint Bone Spine. 2011;78:184–187.
   PubMed Web of Science ®Google Scholar
• Erre G, Sanna P, Zinellu A, et al. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in akylosing spondylitis: A cross-sectional study. Clin Rheumatol. 2011;30:21–27.
   PubMed Web of Science ®Google Scholar
• O’Shea F, Tsui F, Chiu B, et al. Retinol (vitamin A) and retinol binding protein levels are decreased in ankylosing spondylitis: clinical and genetic analysis. J Rheumatol. 2007;34:2457–2459.
   PubMed Web of Science ®Google Scholar
• Genre F, Lopez-Mejias R, Miranda-Filloy J, et al. Antitumour necrosis factor alpha treatment reduces retinol-binding protein 4 serum levels in non-dianetic ankylosing spondylitis patients. Ann Rheum Dis. 2014;73:941–943.
   PubMed Web of Science ®Google Scholar
• Ozgocmen S, Sogus S, Ardicoglu O, et al. Serum nitric oxide, catalase, superoxide dismtase and malondialdehyde stats in patients with ankylsing spondylitis. Rheumatol Int. 2004;24:80–83.
   PubMed Web of Science ®Google Scholar
• Kozaci L, Sari I, Alacacioglu A, et al. Evaluation of inflammation and oxidative stress in ankylosing spondylitis: a role for macrophage migration inhibitory factor. Mod Rheumatol. 2010;20:34–39.
   PubMed Web of Science ®Google Scholar
• Hoffman I, Dmetter P, Peeters M, et al. Anti-saccharomyces cerevisiae IgA antibodies are raised in ankylosing spondylitis and undifferentiated spondyloarthropathy. Ann Rheum Dis. 2003;62:455–459.
   PubMed Web of Science ®Google Scholar
• Aydin SZ, Atagunduz P, Temel M, et al. Anti-saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford). 2008;47:142–144.
   PubMed Web of Science ®Google Scholar
• De Vries M, Van der Horst-Bruinsma I, Van Hoogstraten I, et al. pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease. J Rheumatol. 2010;37:2340–2344.
   PubMed Web of Science ®Google Scholar
• Appel H, Maier R, Wu P, et al. Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther. 2011;13:R95.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Di Cesare A, Laggner U, et al. The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans. PLoS One. 2011;6:e17160.
   PubMed Web of Science ®Google Scholar
• Sarin R, Wu X, Abraham C. Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4 + and CD8 + human T-cell functional responses. Proc Natl Acad Sci. 2011;108:9560–9565.
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Saxena A, Raychaudhuri SP. Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis. Clin Rheumatol. 2015;34:1019–1023.
   PubMed Web of Science ®Google Scholar
• DeLay M, Turner M, Klenk E, et al. HLA-B27 misfolding and the unfolded protein response augment interleukin-23 production and are associated with Th17 activation in transgenic rats. Arthritis Rheum. 2009;60:2633–2643.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Y, Li Y, et al. Increased frequencies of Th22 cells as well as Th17 cells in the peripheral blood of patients with ankylosing spondylitis and rheumatoid arthritis. PLoS One. 2012;7:e31000.
   PubMed Web of Science ®Google Scholar
• Kollnberger S, Bird L, Roddis M. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol. 2004;173:1699–1710.
   PubMed Web of Science ®Google Scholar
• Smith J, Turner M, DeLay M, et al. Endoplasmic reticulum stress and the unfolded protein response are linked to synergistic IFN-β induction via X-box binding protein. Eur J Immmunology. 2008;38:1194–1203.
   PubMed Web of Science ®Google Scholar
• Van Duivenvoorde LM, Dorris ML, Satumtira N, et al. Relationship between inflammation, bone destruction, and osteoproliferation in the HLA-B27/human β2 -microglobulin-transgenic rat model of spondylarthritis. Arthritis Rheum. 2012;64:3210–3219.
   PubMed Web of Science ®Google Scholar
• Tran TM, Dorris ML, Satumtira N, et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum. 2006;54:1317–1327.
   PubMed Web of Science ®Google Scholar
• Hammer RE, Maika SD, Richardson JA, et al. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human Pzm : an animal model of HLRB27-associated human disorders. Cell. 1990;63:1099–1112.
   PubMed Web of Science ®Google Scholar
• Van der Cruyssen B, Ribbens C, Boonen A, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis. 2007;66:1072–1077.
   PubMed Web of Science ®Google Scholar
• Baeten D, Breban M, Lories R, et al. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum. 2013;65:12–20.
   PubMed Web of Science ®Google Scholar
• Takahashi H, Tsuji H, Hashimoto Y, et al. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol. 2010;35:645–649.
   PubMed Web of Science ®Google Scholar
• Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65–70.
   PubMed Web of Science ®Google Scholar
• Melis L, Vandooren B, Kruithof E, et al. Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Ann Rheum Dis. 2010;69:618–623.
   PubMed Web of Science ®Google Scholar